Business Wire

CA-ANDERSEN-GLOBAL

26.2.2021 11:53:13 CET | Business Wire | Pressemeddelelse

Del
Andersen Global styrker sin caribiske platform med Baptiste & Co. Law Firm

Andersen Global udvider til St. Vincent og Grenadinerne med samarbejdsfirmaet Baptiste & Co. Law Firm, og styrker dermed sin caribiske platform og tilføjer yderligere dækning i den sydlige del af regionen.

Baptiste & Co. Law Firm blev grundlagt i 1986 af administrerende partner, René M. Baptiste, som har mere end 40 års erfaring. Ud over grundlæggelsen af firmaet omfatter Renés bedrifter fuldgyldigt medlemskab af advokatsamfundet i St. Vincent og Grenadinerne, Antigua og Barbuda, Saint Kitts og Nevis; offentliggjorte artikler i tidsskriftet International Finance ; to tjenesteperioder som folkevalgt medlem af parlamentet og minister i St. Vincent og Grenadinerne; samt rollen som formand for organisationen af østlige caribiske staters forsamling. Derudover har hun mere end 50 års offentlig tjeneste, hvilket har resulteret i anerkendelse fra Hendes Majestæt Dronning Elizabeth II i form af udnævnelse til Commander of Saint Michael and Saint George (CMG) for tjenester inden for jura, international finans, kultur og politik.

Baptiste & Co. er et full service-advokatfirma, der er specialiseret i konkurs og insolvens, handelsret, kontrakter, familieret, ejendomsret, ejendomsplanlægning, intellektuel ejendomsret (varemærker) og fast ejendom. Firmaet, der er beliggende i Kingstown, yder juridisk rådgivning og tjenester til enkeltpersoner, offentlige og private virksomheder, kreditforeninger, banker, forsikringsselskaber og rederier, samt udenlandske regeringer og statslige virksomheder. Derudover leverer firmaets advokater tjenester i flere retskredse på naboøer og er strategisk placeret for at hjælpe med grænseoverskridende tjenester i ethvert område af firmaets praksisområder.

"Vi er glade for at samarbejde med ligesindede, der forstår og efterlever værdier bestående af gennemsigtighed og uafhængighed," sagde René. "Vores firma har forpligtet sig til at levere omfattende, uovertrufne løsninger, der overgår kundernes forventninger. At samarbejde med Andersen Globals medlemsfirmaer og samarbejdsfirmaer forbedrer vores evne til at levere synergistiske tjenester til vores kunder på både lokalt og internationalt niveau."

Bestyrelsesformand for Andersen Global og administrerende direktør for Andersen, Mark Vorsatz, tilføjede: "Vi har udviklet en stærk tilstedeværelse i Caribien og vil fortsætte med at tilføje bredde og dybde til vores platform i regionen. René og hendes teams engagement i forvaltning, mange års erfaring og viden om lokale og internationale retskredse adskiller dem fra andre firmaer på markedet. Tilføjelsen af Baptiste & Co. er endnu et vigtigt link til vores strategi i regionen."

Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer bestående af skatte- og juraeksperter fra hele verden. Efter at være blevet etableret i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 7.000 eksperter globalt og er repræsenteret på mere end 255 lokaliteter via sine medlems- og samarbejdsfirmaer.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye